Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular Age-related Macular Degeneration

Overview

To evaluate the safety, efficacy and pharmacokinetics of repeated intravitreal administration of ALT-L9 2 mg/50uL compared with Eylea in patients with neovascular Age-related macular degeneration.

Full Title of Study: “A Phase I Clinical Study of ALT-L9 in Patients With Neovascular Age-related Macular Degeneration”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: October 2020

Interventions

  • Biological: Eylea
    • Aflibercept
  • Biological: ALT-L9
    • Aflibercept biosimilar

Arms, Groups and Cohorts

  • Experimental: ALT-L9
    • Intravitreal injection of ALT-L9 50 ul, every 4 weeks
  • Active Comparator: Eylea
    • Intravitreal injection of Eylea 50 ul, every 4 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Occurrences of adverse events
    • Time Frame: 8 weeks
    • Check the adverse events in study eye at the assessment points after triple administration

Participating in This Clinical Trial

Inclusion Criteria

1. Patients aged 50yeras old or more at the time of consent.

2. Patients with any history of anti-VEGF treatment(Aflibercept, Bevacizumab, Ranibizumab) for neovascular AMD in the study eye.

3. Patients who were treated with the last anti-VEGF at least 8 weeks prior to study drug administration.

4. Patients with untreated active primary subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye at the start of the screening visit.

5. Patients with subretinal, intraretinal, or subretinal pigment epithelium fluid as assessed by SD-OCT in the study eye at the start of the screening visit.

6. Patients who have CNV which is at least 50% of total lesion size in the study eye at the start of the screening visit.

7. Patients with ETDRS best-corrected visual acuity of 20/40 to 20/320 (letter score of 73 to 25) in the study eye at the start of the administration of the study drug.

8. Patients with ETDRS best-corrected visual acuity of 20/400 (letter score 20) or better in the fellow eye at the start of the administration of the study drug.

Exclusion Criteria

1. Patients who have received any prior ocular (in the study eye) or systemic treatment for neovascular AMD within 8 weeks from the screening date except dietary supplements or vitamins.

2. Patients who have received any surgery for neovascular AMD.

3. Patients with any current or history of macular or retinal disease other than neovascular AMD (eg, diabetic macular edema, retinal vein occlusion, pathological myopia, angioid streaks, ocular histoplasmosis, trauma, retinal detachment, epiretinal membrane, macular hole, central serous chorioretinopathy, Choroidal rupture, Multiple network choroiditis, proliferative diabetic retinopathy) in the study eye.

4. Patients with scar, fibrosis, or atrophy involving the center of the fovea in the study eye that might interfere with visual acuity.

5. Patients with hemorrhage under the fovea or subretinal hemorrhage 50% or more of the total lesion area in the study eye.

6. Patients with retinal pigment epithelial tears or rips involving the macula in the study eye.

7. Patients with a history of any vitreous hemorrhage or rhegmatogenous retinal detachment in the study eye within 4 weeks before the start of the administration of the study drug.

8. Patients who have received panretinal photocoagulation in the study eye.

9. Patients who have received vitreous surgery in the study eye.

10. Patients with a history of corneal transplant or corneal dystrophy in the study eye.

11. Patients who have received cataract surgery or Lasik in the study eye within 90 days before the start of the administration of the study drug.

12. Patients who have received trabeculectomy or other filtration surgery in the study eye.

13. Patients with poorly controlled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment with antiglaucoma medication) in the study eye.

14. Patients with significant media opacities, including cataract, in the study eye that might interfere with visual acuity, assessment of safety, or fundus photography considered by the principal investigator or investigator.

15. Patients with any diseases in the study eye that could have compromised visual acuity such as amblyopia and anterior ischemic optic neuropathy considered by the principal investigator or investigator.

16. Patients with cataract in the study eye that could have required medical or surgical intervention during the course of the study considered by the principal investigator or investigator.

17. Patients with aphakia with absence of posterior capsule (in the study eye.

18. Patients who have received therapeutic radiation in the region of the study eye.

19. Patients who use topical ocular corticosteroids for 30, or more, consecutive days within 90 days before the screening visit, or have a plan or actual use for 30 or more consecutive days during the course of the study in the study eye.

Criteria for fellow eye or either eye:

20. Patients with any active intraocular or periocular infection or intraocular inflammation in either eye (eg, infectious blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis).

21. Patients with a history of uveitis in either eye.

22. Patients with a concurrent or history of scleromalacia in either eye.

23. Patients who have received anti-VEGF medication in the fellow eye within 8 weeks before the start of the administration of the study drug.

Other criteria:

24. Patients who use systemic corticosteroids for 30 or more consecutive days within 90 days before the Screening Visit, or have a plan or actual use for 30 or more consecutive days during the course of the study. Inhaled steroids were permitted.

25. Patients who use steroid(except systemic or inhaled steroid) within 6 months, or have a plan for use of steroid during the course of the study.

26. Patients with poorly controlled hypertension. (defined as systolic BP is 160 mmHg or more or diastolic BP is 100 mmHg or more despite medication)

27. Patients with a serious liver, kidney or cardiovascular disorders considered by the principal investigator or investigator.

28. Patients with a concurrent or history of malignancy within 5 years before informed consent.

29. Patients with drug abuse (defined as use of illegal drugs) or alcohol dependence or a history of these conditions.

30. Patients with a history of clinically significant drug hypersensitivity.

31. Patients with a history of allergy to aflibercept, fluorescein, indocyanine green and povidone iodine.

32. Patients with any contraindications described in aflibercept package insert.

33. Females who are pregnant, breastfeeding, or of childbearing potential, unwilling to practice adequate contraception throughout the study.

34. Patients with type 1 diabetes or increase of HbA1c(>12%).

35. Patients who have received any other investigational drug within 12 weeks before screening visit.

36. Other patients considered by the principal investigator or investigator to be inappropriate as subjects.

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Alteogen, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.